Merit Medical Systems, Inc. — FY 2012 Form 10-K
Business context and reporting period. This annual report covers the fiscal year ended December 31, 2012; quarterly figures below identify the fourth quarter. Merit designs and sells single-use medical devices for diagnostic and interventional procedures. Its reportable segments are cardiovascular and endoscopy. The financial statements received an unqualified audit opinion; management and the auditor reported effective internal controls, although Thomas Medical was excluded from part of the control assessment following its late-December acquisition.
Financial performance and liquidity
| Metric | FY 2012 | FY 2011 |
|---|---|---|
| Net sales | $394.3 million | $359.4 million |
| Gross profit / margin | $182.0 million / 46.2% | $165.5 million / 46.0% |
| Operating income / margin | $29.6 million / 7.5% | $33.2 million / 9.2% |
| Net income | $19.7 million | $23.0 million |
| Diluted EPS | $0.46 | $0.58 |
| Cash from operations | $46.9 million | $34.0 million |
| Capital expenditures | $64.6 million | $59.2 million |
FY 2012 sales grew 9.7%, while net income fell about 14.5%. Gross margin was broadly stable, but SG&A rose 17% to $122.1 million and R&D rose 27% to $27.8 million, contributing to lower operating income. Diluted weighted-average shares rose to 42.6 million from 39.7 million.
Fourth-quarter sales were $102.2 million versus $91.1 million a year earlier; operating income was $4.3 million versus $5.6 million and net income was $0.6 million versus $5.0 million. Management attributed the Q4 net-income decline primarily to Thomas Medical acquisition-related costs and a $2.4 million impairment of a cost-method investment.
At year-end, cash and cash equivalents were $9.7 million, working capital was $89.0 million, current assets were $162.0 million, and total assets were $705.3 million. Total debt was $237.6 million, including $10.0 million current and $227.6 million long-term; available borrowing capacity was approximately $33.8 million, subject to the credit agreement’s leverage terms. Operating cash flow increased, while investing activities used $255.6 million, principally reflecting acquisitions and capital spending. Cash was nearly unchanged from year-end 2011.
Material changes and business developments
- International sales rose 16% to $146.3 million, or 37% of sales, from $125.9 million, or 35%. U.S. sales represented 63% of total sales.
- Cardiovascular sales increased 8.9% to $378.5 million. Endoscopy sales rose 31.4% to $15.8 million; its operating loss narrowed to $0.8 million from $4.8 million. Cardiovascular operating income declined to $30.4 million from $38.0 million.
- Merit acquired Thomas Medical in December for approximately $165.6 million net of acquired cash. Only $1.9 million of its 2012 sales was included after closing. Other 2012 transactions included Ostial Solutions and MediGroup.
- Year-end debt increased substantially following the Thomas Medical acquisition. The company entered into a new secured credit agreement with a $100 million term loan and a revolving commitment of up to $175 million; $150 million of debt was fixed at 2.98% through an interest-rate swap.
Outlook, risks and contingencies
- Management identified no formal earnings guidance in the provided filing text. It expected approximately $46 million of 2013 capital expenditures, including $18 million for building construction.
- Management estimated that the medical-device excise tax would reduce 2013 gross profit and earnings by $3.5–$4.0 million on direct U.S. hospital sales. New U.S. facilities were expected to add approximately $2.5–$3.5 million of costs to 2013 gross margins, operating expenses and earnings during transition.
- Management expected lower costs from a newly qualified endoscopy stent manufacturer to begin supporting margins in the second quarter of 2013 and to help the segment move toward profitability. It also described a pipeline of planned 2013 product launches; these are expectations, not assured outcomes.
- Key risks include device regulation and product liability, reimbursement and healthcare reform, competitive and technology changes, supplier and sterilization concentration, foreign-exchange exposure, acquisition integration, inventory obsolescence, and dependence on cash generation and debt-covenant compliance. The 2.3% medical-device excise tax began January 1, 2013.
- The FDA issued a warning letter in February 2012 concerning a coating-process change to the Merit Laureate guidewire. Merit temporarily stopped U.S. distribution, obtained 510(k) clearance in September, resumed sales, and received an October FDA letter stating the violation appeared addressed.
- Other notable exposures include $6.7 million of contingent acquisition consideration, $19.5 million of operating lease commitments, and approximately $3.0 million of Irish grants potentially repayable if production there ceases before the applicable period ends. The company reported that it did not expect to repay those grants and did not believe ordinary-course litigation was likely to be material.
Important facts for investors to verify
- How much of future growth and earnings depends on integrating Thomas Medical and realizing the expected tax benefits and commercial synergies.
- Whether 2013 excise-tax and facility-transition costs, planned capital spending, and debt covenants affect margins, free cash flow, or borrowing capacity as management anticipated.
- Whether endoscopy reaches profitability and whether planned product launches, clinical trials, and regulatory clearances progress on schedule.
- Whether international growth persists and how currency movements, reimbursement changes, pricing pressure, and supplier availability affect results.
- How acquisition-related contingent consideration, inventory growth, and the significant rise in debt evolve; confirm actual cash flow and debt repayment against the filing’s forecasts.